|
業務類別
|
Biotechnology |
|
業務概覽
|
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe. |
| 公司地址
| C/O Theravance Biopharma US, LLC, 901 Gateway Boulevard, South San Francisco, CA, USA, 94080 |
| 電話號碼
| +1 650 808-6000 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.theravance.com |
| 員工數量
| 90 |
| Ms. Rhonda Farnum |
Chief Business Officer and Senior Vice President, Commercial and Medical Affairs |
美元 506.30K |
28/04/2026 |
| Mr. Aziz Sawaf, C.F.A. |
Senior Vice President, Chief Financial Officer and Principal Accounting Officer |
-- |
28/04/2026 |
| Dr. Aine Miller, PhD |
Senior Vice President, Development and Head, Ireland Office |
美元 506.23K |
28/04/2026 |
| Mr. Rick E. Winningham |
Director and Chief Executive Officer |
美元 1.05M |
28/04/2026 |
| Mr. Brett A. Grimaud |
Senior Vice President, General Counsel and Secretary |
-- |
28/04/2026 |
|
|
| Mr. Donal O’Connor |
Independent Director |
28/04/2026 |
| Dr. Laurie Smaldone Alsup, M.D. |
Independent Director |
28/04/2026 |
| Mr. Rick E. Winningham |
Director and Chief Executive Officer |
28/04/2026 |
| Dr. Deepika Rachel Pakianathan |
Independent Director |
28/04/2026 |
| Mr. Eran Broshy |
Independent Director |
28/04/2026 |
| Mr. Dean Jonathan Mitchell |
Independent Director |
28/04/2026 |
| Mr. James C. Kelly |
Independent Director |
28/04/2026 |
| Mr. Jeremy Grant |
Independent Director |
28/04/2026 |
| Ms. Susannah Gray, M.B.A. |
Chairman of the Board |
28/04/2026 |
|
|
|
|
